trabecular meshwork

PSLT shows promise in lowering intraocular pressure Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.
Shaffer Prize report goes down one path, but leads to anotherResearch aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.
Single-use MIGS device demonstrates significant reduction in IOP in retrospective studyTrabecular bypass procedures have become a viable option for glaucoma treatment. The Kahook Dual Blade (KDB) facilitates ab interno trabeculectomy by employing a single-use, micro-engineered excision blade that makes precise parallel incisions in the trabecular meshwork and inner wall of the Schlemm’s canal to enhance aqueous outflow. A recent study highlights the effectiveness of its application.
Managing glaucoma with surgical procedures (plural)The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
Exploring risk, reward in trabecular bypass, suprachoroidal devices
Exploring risk, reward in trabecular bypass, suprachoroidal devicesThough much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.
New dual blade can help surgeons lower IOPA new trabecular meshwork excision blade takes a new approach in IOP reduction.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Nitric oxide: A potential target for glaucoma treatmentEvidence suggests that nitric oxide can modify both mechanical and vascular events in primary open-angle glaucoma pathogenesis.
Directly targeting pathology: A novel approach to treating glaucomaRho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.
Phase I trial for ISTH0036 advanced glaucoma treatmentIsarna Therapeutics has begun a Phase I clinical trial of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2), to treat advanced glaucoma.